{"id":2979,"date":"2018-03-08T14:00:00","date_gmt":"2018-03-08T14:00:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/information-fran-xvivo-perfusions-valberedning-2\/"},"modified":"2018-03-08T14:00:00","modified_gmt":"2018-03-08T14:00:00","slug":"information-fran-xvivo-perfusions-valberedning-2","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/information-fran-xvivo-perfusions-valberedning-2\/","title":{"rendered":"Information fr\u00e5n XVIVO Perfusions Valberedning"},"content":{"rendered":"

XVIVO Perfusion ABs valberedning f\u00f6resl\u00e5r inf\u00f6r \u00e5rsst\u00e4mman den 27 april 2018 omval av G\u00f6sta Johannesson, Erik von Schenck, Camilla \u00d6berg och Folke Nilsson. Fredrik Mattsson och Semmy R\u00fclf har avb\u00f6jt omval.<\/span><\/p>\n

Valberedningen f\u00f6resl\u00e5r nyval av G\u00f6sta Johannesson som styrelsens ordf\u00f6rande. D\u00e4rut\u00f6ver f\u00f6resl\u00e5r valberedningen Yvonne M\u00e5rtensson och Alan Raffensperger som nya ledam\u00f6ter.<\/span><\/p>\n

Yvonne M\u00e5rtensson har en l\u00e5ng och gedigen erfarenhet fr\u00e5n medicinteknik och life science, n\u00e4rmast fr\u00e5n rollen som VD f\u00f6r CellaVision AB under \u00e5ren 1998-2014. Yvonne M\u00e5rtensson har ocks\u00e5 en l\u00e5ng erfarenhet av styrelsearbete inom teknik och life scince. Yvonne M\u00e5rtensson har en M.Sc. i Industrial Engineering and Management fr\u00e5n Tekniska h\u00f6gskolan vid Link\u00f6pings Universitet.<\/span><\/p>\n

Alan Raffensperger <\/span>har en l\u00e5ng och gedigen erfarenhet fr\u00e5n medicinteknik och life science. Alans nuvarande uppdrag \u00e4r som VD f\u00f6r Inceptua SA och innan dess som COO f\u00f6r SOBI (Swedish Orphan Biovitrum AB) under \u00e5ren 2012-2017. Mellan \u00e5ren 2010-2012 var Alan Raffensperger VD f\u00f6r Benechill Inc. Alan Raffensperger har en MBA fr\u00e5n George Washington University och B.Sc. i Health Services Management fr\u00e5n Univerity of Maryland Baltimore.<\/span><\/p>\n

Valberedningens \u00f6vriga f\u00f6rslag kommer att offentligg\u00f6ras i kallelsen till \u00e5rsst\u00e4mman.<\/span><\/p>\n

XVIVO Perfusions valberedning utg\u00f6rs av<\/span> Henrik Blomquist, utsedd av Bure Equity AB, Martin Lewin, utsedd av Eccenovo AB\u00a0<\/span>och Joachim Spetz, utsedd av Swedbank Robur. Valberedning har utsetts i enlighet med den instruktion som fastst\u00e4lldes vid \u00e5rsst\u00e4mma i XVIVO Perfusion AB (publ) den 3 maj 2016.<\/p>\n

\u00c5rsst\u00e4mman \u00e4ger rum den 27 april 2018 i G\u00f6teborg.<\/span><\/p>\n

XVIVO Perfusion AB (publ)<\/span><\/p>\n

Kontaktperson:\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0
<\/span>Henrik Blomquist
Valberedningens ordf\u00f6rande\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0
Tel: 08 \u2013 614 00 20
henrik.blomquist@bure.se
XVIVO Perfusion AB (publ)<\/p>\n

\n

F\u00f6r ytterligare information om XVIVO Perfusions verksamhet h\u00e4nvisas till bolagets hemsida, www.xvivoperfusion.com<\/span><\/p>\n

Denna information \u00e4r s\u00e5dan information som Xvivo Perfusion AB (publ) \u00e4r skyldigt att offentligg\u00f6ra enligt lagen om v\u00e4rdepappersmarknaden. Informationen l\u00e4mnades f\u00f6r offentligg\u00f6rande klockan 15:00 den 8 mars 2018.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

XVIVO Perfusion ABs valberedning f\u00f6resl\u00e5r inf\u00f6r \u00e5rsst\u00e4mman den 27 april 2018 omval av G\u00f6sta Johannesson, Erik von Schenck, Camilla \u00d6berg…<\/p>\n","protected":false},"template":"","class_list":["post-2979","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-listing","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-other"],"acf":[],"yoast_head":"\nInformation fr\u00e5n XVIVO Perfusions Valberedning - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/information-fran-xvivo-perfusions-valberedning-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Information fr\u00e5n XVIVO Perfusions Valberedning - XVIVO\" \/>\n<meta property=\"og:description\" content=\"XVIVO Perfusion ABs valberedning f\u00f6resl\u00e5r inf\u00f6r \u00e5rsst\u00e4mman den 27 april 2018 omval av G\u00f6sta Johannesson, Erik von Schenck, Camilla \u00d6berg...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/information-fran-xvivo-perfusions-valberedning-2\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/information-fran-xvivo-perfusions-valberedning-2\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/information-fran-xvivo-perfusions-valberedning-2\\\/\",\"name\":\"Information fr\u00e5n XVIVO Perfusions Valberedning - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2018-03-08T14:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/information-fran-xvivo-perfusions-valberedning-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/information-fran-xvivo-perfusions-valberedning-2\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/information-fran-xvivo-perfusions-valberedning-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Information fr\u00e5n XVIVO Perfusions Valberedning\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Information fr\u00e5n XVIVO Perfusions Valberedning - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/information-fran-xvivo-perfusions-valberedning-2\/","og_locale":"en_US","og_type":"article","og_title":"Information fr\u00e5n XVIVO Perfusions Valberedning - XVIVO","og_description":"XVIVO Perfusion ABs valberedning f\u00f6resl\u00e5r inf\u00f6r \u00e5rsst\u00e4mman den 27 april 2018 omval av G\u00f6sta Johannesson, Erik von Schenck, Camilla \u00d6berg...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/information-fran-xvivo-perfusions-valberedning-2\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/information-fran-xvivo-perfusions-valberedning-2\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/information-fran-xvivo-perfusions-valberedning-2\/","name":"Information fr\u00e5n XVIVO Perfusions Valberedning - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2018-03-08T14:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/information-fran-xvivo-perfusions-valberedning-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/information-fran-xvivo-perfusions-valberedning-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/information-fran-xvivo-perfusions-valberedning-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"Information fr\u00e5n XVIVO Perfusions Valberedning"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/2979","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=2979"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}